Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by K. Joseph Hurt
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, K. Hurt wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Pancreatic Cancer in Pregnancy Presenting with Thromboembolic Events: Case Report and Review of the Literature. 2018

Wakefield, Brian W / Masterson, Crystal M C / Borges, Manuel T / Hurt, K Joseph. ·Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado, USA. · University of Colorado College of Nursing, Aurora, Colorado, USA. · Department of Neuroradiology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. ·Gynecol Obstet Invest · Pubmed #29886492.

ABSTRACT: Stroke and hepatic vein thrombosis are highly associated with neoplasia but are extremely rare events in young, pregnant women. Rare and recurrent thrombotic events in pregnancy increase the suspicion for occult malignancy. We describe the case of a healthy 31-year-old G2P1 who presented with visual changes and dysarthria during pregnancy. Imaging showed cerebral infarcts. Her thrombophilia evaluation was negative. During delivery, she was diagnosed with fulminant Budd-Chiari Syndrome. Hepatic ultrasound suggested malignancy or metastasis, and postpartum CT scan and biopsy confirmed the diagnosis of Stage IV pancreatic cancer. Although rare in pregnancy, a new diagnosis of malignancy should be considered in patients with recurrent unexplained hypercoagulable complications. We propose an evidence-based algorithm for evaluation of occult malignancy in pregnancy based upon this case and review of the literature.

2 Clinical Trial A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. 2017

Laquente, Berta / Lopez-Martin, Jose / Richards, Donald / Illerhaus, Gerald / Chang, David Z / Kim, George / Stella, Philip / Richel, Dirk / Szcylik, Cezary / Cascinu, Stefano / Frassineti, G L / Ciuleanu, Tudor / Hurt, Karla / Hynes, Scott / Lin, Ji / Lin, Aimee Bence / Von Hoff, Daniel / Calvo, Emiliano. ·Institut Català d'Oncologia-IDIBELL (Institut d'Investigació Biomèdica de Bellvitge), Barcelona, Spain. · University Hospital and Research Institute, Madrid, Spain. · US Oncology Research, Tyler, USA. · Hematology, Onkology, and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany. · Virginia Oncology Associates, Eastern Virginia Medical School, US Oncology Research, Hampton, VA, USA. · 21st Century Oncology, University of Florida Health Oncology, Jacksonville, USA. · St. Joseph Mercy Hospital, Ypsilanti, MI, USA. · Academic Medical Center, Amsterdam, Netherlands. · Department of Oncology, Military Institute of Medicine, Warsaw, Poland. · Department of Oncology and Hematology, Universitá di Modena e Reggio Emilia, Policlinico di Modena, Modena, Italy. · Department of Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. · Institute of Oncology Ion Chiricuta, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania. · Eli Lilly and Company, Indianapolis, IN, USA. · Translational Genomics Research Institute (TGen) and HonorHealth Research Institute, Phoenix, AZ, USA. · START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Division, Hospital Universitario Madrid Norte Sanchinarro, Calle Oña, 10, 28050, Madrid, Spain. emiliano.calvo@start.stoh.com. ·BMC Cancer · Pubmed #28202004.

ABSTRACT: BACKGROUND: The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. METHODS: Patients with Stage II-IV locally advanced or metastatic pancreatic cancer were randomized (2:1) to either 230 mg of LY2603618/1000 mg/m RESULTS: Ninety-nine patients (n = 65, LY2603618/gemcitabine; n = 34, gemcitabine) were randomized (intent-to-treat population). The median OS (months) was 7.8 (range, 0.3-18.9) with LY2603618/gemcitabine and 8.3 (range, 0.8-19.1+) with gemcitabine. Similarly, in a Bayesian analysis, the study was not positive since the posterior probability that LY2603618/gemcitabine was superior to gemcitabine in improving OS was 0.3, which did not exceed the prespecified threshold of 0.8. No significant improvements in PFS, ORR, or duration of response were observed. Drug-related treatment-emergent AEs in both arms included nausea, thrombocytopenia, fatigue, and neutropenia. The severity of AEs with LY2603618/gemcitabine was comparable to gemcitabine. The LY2603618 exposure targets (AUC CONCLUSIONS: LY2603618/gemcitabine was not superior to gemcitabine for the treatment of patients with pancreatic cancer. TRIAL REGISTRATION: NCT00839332 . Clinicaltrials.gov. Date of registration: 6 February 2009.